» Articles » PMID: 36910476

The Mast Cell Exosome-fibroblast Connection: A Novel Pro-fibrotic Pathway

Overview
Specialty General Medicine
Date 2023 Mar 13
PMID 36910476
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: In addition to the traditional activation of resident receptors by release of local mediators, new evidence favors the existence of exosomes in cell-to-cell communication that mediates delivery of specific cargo to modulate recipient cell function. We report that mast cell exosomes are an additional source of pro-fibrotic substances and constitute a unique pathway for the generation of excess collagen.

Methods: We use primary human lung fibroblasts (HLFs) to demonstrate the uptake of labeled exosomes isolated from the human mast cell line HMC-1 (MC-EXOs), previously shown to contain protein cargo in common with human mast cell exosomes.

Results: The MC-EXO uptake by HLF is to the cytosol and increases both proline hydroxylation in HLF lysate and secreted collagen, within 24 h, which is sustained over 72 h, the same time required for transforming growth factor-β (TGF-β) to activate collagen synthesis in the HLFs. Unlike TGF-β, MC-EXO uptake does not induce fibrillar gene activation or invoke the Smad-nuclear transcription pathway. We show that MC-EXO uptake and TGF-β have an additive effect on collagen synthesis in HLF and postulate that MC-EXO uptake by HLFs is a contributing factor to excess collagen synthesis and represents a unique paradigm for understanding fibrosis.

Discussion: It is known that, in the lungs, mast cells are more activated and increase in number with inflammation, injury and viral infection associated with fibrosis. With the reported increased incidence of post-COVID-pulmonary fibrosis (PCPF), data from patients with severe COVID-19 are presented that show an increase in the mast cell number in lung parenchyma, the site of PCPF. Our findings provide a rationale for targeting multiple fibrogenic pathways in the management of lung fibrosis and the use of mast cell exosomes as a biomarker for the prognostic and diagnostic management of evolving fibrotic lung disease.

Citing Articles

Impact of Minimally Manipulated Cell Therapy on Immune Responses in Radiation-Induced Skin Wound Healing.

Shestakova V, Smirnova E, Atiakshin D, Kisel A, Koryakin S, Litun E Int J Mol Sci. 2025; 26(5).

PMID: 40076619 PMC: 11900442. DOI: 10.3390/ijms26051994.


Immunomodulatory Significance of Mast Cell Exosomes (MC-EXOs) in Immune Response Coordination.

Elieh-Ali-Komi D, Shafaghat F, Alipoor S, Kazemi T, Atiakshin D, Pyatilova P Clin Rev Allergy Immunol. 2025; 68(1):20.

PMID: 39976807 PMC: 11842441. DOI: 10.1007/s12016-025-09033-6.


IL-10 Modulates the Expression and Activation of Pattern Recognition Receptors in Mast Cells.

Riquelme-Neira R, Walker-Vergara R, Fernandez-Blanco J, Vergara P Int J Mol Sci. 2023; 24(12).

PMID: 37373041 PMC: 10298310. DOI: 10.3390/ijms24129875.


A survey of the currently known mast cell mediators with potential relevance for therapy of mast cell-induced symptoms.

Molderings G, Afrin L Naunyn Schmiedebergs Arch Pharmacol. 2023; 396(11):2881-2891.

PMID: 37243761 PMC: 10567897. DOI: 10.1007/s00210-023-02545-y.

References
1.
Tharp M, Seelig Jr L, Tigelaar R, Bergstresser P . Conjugated avidin binds to mast cell granules. J Histochem Cytochem. 1985; 33(1):27-32. DOI: 10.1177/33.1.2578142. View

2.
George P, Wells A, Gisli Jenkins R . Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020; 8(8):807-815. PMC: 7228727. DOI: 10.1016/S2213-2600(20)30225-3. View

3.
Murdaca G, Di Gioacchino M, Greco M, Borro M, Paladin F, Petrarca C . Basophils and Mast Cells in COVID-19 Pathogenesis. Cells. 2021; 10(10). PMC: 8534912. DOI: 10.3390/cells10102754. View

4.
Graham A, Temple R, Obar J . Mast cells and influenza a virus: association with allergic responses and beyond. Front Immunol. 2015; 6:238. PMC: 4435071. DOI: 10.3389/fimmu.2015.00238. View

5.
Vancheri C, Kreuter M, Richeldi L, Ryerson C, Valeyre D, Grutters J . Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. Am J Respir Crit Care Med. 2017; 197(3):356-363. DOI: 10.1164/rccm.201706-1301OC. View